Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting
24 avr. 2024 16h05 HE
|
Erasca, Inc.
Oral presentation will feature updated HERKULES-3 results for ERK1/2 inhibitor ERAS-007 in combination with encorafenib and cetuximab in BRAFm colorectal cancer Poster presentations will feature...
Erasca Announces $45 Million Oversubscribed Private Placement Financing
27 mars 2024 20h30 HE
|
Erasca, Inc.
SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS) (“Erasca”), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing...
Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results
27 mars 2024 16h01 HE
|
Erasca, Inc.
Gained global registrational clarity for naporafenib and achieved key clinical milestones for naporafenib, ERAS-007, and ERAS-801 Multiple data readouts expected in 2024 for naporafenib...
Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials
14 févr. 2024 08h00 HE
|
Erasca, Inc.
Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor in multiple RAS/MAPK pathway-driven tumors Initial SEACRAFT-1 Phase 1b combination data in RAS Q61X solid tumors expected...
Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
01 févr. 2024 08h00 HE
|
Erasca, Inc.
SAN DIEGO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 janv. 2024 08h00 HE
|
Erasca, Inc.
SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma
11 déc. 2023 08h00 HE
|
Erasca, Inc.
First-in-class and best-in-class potential in NRAS-mutated melanoma and other RAS/MAPK pathway-altered solid tumors Naporafenib has been dosed in more than 500 patients to date, establishing its...
Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway
28 nov. 2023 08h00 HE
|
Erasca, Inc.
Gained alignment with global health authorities for pivotal Phase 3 SEACRAFT-2 trial design for naporafenib plus trametinib in NRAS mutant melanoma; initiation on track for H1 2024 Completed dose...
Erasca Reports Third Quarter 2023 Financial Results and Business Updates
09 nov. 2023 16h01 HE
|
Erasca, Inc.
First patient dosed in SEACRAFT-1 Phase 1b trial evaluating naporafenib plus trametinib Multiple upcoming catalysts across ongoing clinical programs Strong balance sheet with cash, cash equivalents,...
Erasca to Present at Upcoming Investor Conferences in November
08 nov. 2023 08h00 HE
|
Erasca, Inc.
SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...